好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-014

Demonstrate how three dimensional (3D) brain MRI can be visualized utilizing the topographical model of multiple sclerosis (MS) to facilitate assessment of MS disease burden.

Brain MRIs contain hundreds of images across an array of sequences, and standard radiology reports may not comprehensively convey the total burden of disease.

The topographical model of MS was developed as a visualization of MS that depicts localized lesions in a pool of variable reserve. To date, this model has only been used to show emblematic disease phenotypes rather than utilizing MRI data to depict individual patient data. We present the first visualizations of patients in the topographical model using novel 3D brain MRI technology.

Using a well-characterized cohort of patients with relapsing-remitting multiple sclerosis (PwMS), case-depiction feasibility was assessed utilizing MRIs with 3D T1 & T2 FLAIR sequences, processed through NeuroQuantMS 3.1 (cortechs.ai) and THINQ (Corticometrics) to extract lesion counts and volumes, parenchymal volumetrics, and 3D surface meshes. Volumetric and lesion meshes were then grouped into FBX files and imported into Unity, in which lesion localizations were mapped and scaled for depiction according to topographical model parameters.

Novel visualizations of PwMS in the topographical model will be shown, demonstrating the feasibility of this technique to depict radiographic burden of disease. Each 3D brain MRI is paired with topographical model rendering showing lesion size/severity, surface morphology, and laterality/localization in juxtacortical, subcortical, periventricular, and segmented infratentorial regions. Clinical factors including age, sex, race, disease duration, current treatment, and Patient Determined Disease Steps (PDDS) are shown for each PwMS.

3D brain visualizations in tandem with the topographical model of MS convey disease burden in an intuitive format emphasizing the importance of lesion localization, with potential as an educational/communication tool. Future iterations will seek to incorporate spinal cord MRI and depict functional reserve using parenchymal volumetrics.

Authors/Disclosures
Stephen Krieger, MD, FAAN (Mount Sinai Dept of Neurology)
PRESENTER
Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb. The institution of Dr. Krieger has received research support from Biogen. The institution of Dr. Krieger has received research support from Sanofi.
Patricia Izbicki, PhD (Octave) Dr. Izbicki has received personal compensation for serving as an employee of Octave. Dr. Izbicki has received personal compensation for serving as an employee of AbbVie. Dr. Izbicki has received personal compensation in the range of $0-$499 for serving as a Speaker with Palm Health Foundation. Dr. Izbicki has a non-compensated relationship as a Board Member with Giving Voice Initiative that is relevant to AAN interests or activities. Dr. Izbicki has a non-compensated relationship as a Board Member with Mind, Music, and Movement Foundation that is relevant to AAN interests or activities.
Kelly Leyden, MRes (Octave Bioscience) Ms. Leyden has received personal compensation for serving as an employee of Octave.
Lynden Bajus (Octave Bioscience) No disclosure on file
Daniel Peterson (Octave Bioscience) No disclosure on file
Michael Schrier No disclosure on file
Emily Ding No disclosure on file
VIDYA KESHAVAN (Octave Bioscience) No disclosure on file
Tamara Hoyt (Rocky Mountain MS Research Group) Ms. Hoyt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono.
John F. Foley, MD, FAAN (Rocky Mountain MS Clinic) The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave. Dr. Foley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Foley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Foley has stock in InterPRO Bioscience. The institution of Dr. Foley has received research support from Biogen. The institution of Dr. Foley has received research support from Novartis. The institution of Dr. Foley has received research support from Octave. The institution of Dr. Foley has received research support from Genentech. The institution of Dr. Foley has received research support from Imstem. The institution of Dr. Foley has received research support from Aegir.